Meningococcal polysaccharide vaccines: A review

Carbohydrate Polymers

Volumn 75, Issue 4, 2009, Pages 553-565

  Joshi, Varsha S ^a   Bajaj, Ishwar B ^a   Survase, Shrikant A ^a   Singhal, Rekha S ^a   Kennedy, John F ^b  

^a UNIVERSITY OF MUMBAI   (India)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Bacterial meningitis; Neisseria meningitidis; Outer membrane vesicle; Polysaccharide conjugate vaccines; Polysaccharide vaccines

Indexed keywords

BACTERIOLOGY; BIOPOLYMERS; VACCINES;

ACTIVE COMPONENTS; ANALYTICAL TECHNIQUES; BACTERIAL MENINGITIS; CAPSULAR POLYSACCHARIDES; CONVENTIONAL APPROACHES; FERMENTATIVE PRODUCTIONS; IMMUNOGENICITY; MENINGITIDIS; NEISSERIA MENINGITIDIS; OUTER MEMBRANE VESICLE; QUANTITATIVE DETERMINATIONS; SEROGROUPS;

POLYSACCHARIDES;

BACTERIA (MICROORGANISMS); NEISSERIA MENINGITIDIS;

EID: 57749186681     PISSN: 01448617     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.carbpol.2008.09.032     Document Type: Review

References (96)

1. Anderson R.M., Donnelly C.A., and Gupta S. Vaccine design, evaluation, and community-based use for antigenically variable infectious agents. The Lancet 350 (1997) 1466-1470
2. Anderson E.L., Bowers T., Mink C.M., Kennedy D.J., Belshe R.B., Harakeh H., et al. Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults. Infection and Immunity 62 8 (1994) 3391-3395
3. Ball R., Braun M., and Mootrey G. Safety data on meningococcal polysaccharide vaccine from the vaccine adverse event reporting system. Clinical Infectious Diseases 32 9 (2001) 1273-1280
4. Banerjee-Bhatnagar N., and Frasch C.E. Expression of Neisseria meningitidis iron-regulated outer membrane proteins, including a 70-kilodalton transferrin receptor, and their potential for use as vaccines. Infection and Immunity 58 (1990) 2875-2881
5. Baruque-Ramos J., Paz M.F.D., Hiss H., Vincentin M.A., Leal B., and Raw I. Nitrogen consumption during batch cultivation of Neisseria meningitidis (serogroup C) in Frantz medium. Brazilian Journal of Microbiology 32 4 (2001) 305-310
6. Beuvery E.C., Miedema F., Delft R.V., and Haverkamp J. Preparation and immunochemical characterization of meningococcal group C polysaccharide-tetanus toxoid conjugates as a new generation of vaccines. Infection and Immunity 40 (1983) 39-45
7. Bhattacharjee A.K., Jennings H.J., Kenny C.P., Martin A., and Smith I.C. Structural determination of the sialic acid polysaccharide antigens of Neisseria meningitidis serogroups B and C with carbon 13 nuclear magnetic resonance. Journal of Biological Chemistry 250 (1975) 1926-1932
8. Bjune G., Gronnesby J.K., Hoiby E.A., Closs O., and Nokleby H. Results of an efficacy trial with an outer membrane vesicle vaccine against systemic serogroup B meningococcal disease in Norway. NIPH Annals 14 (1991) 125-130
9. Borrow R., Clark S., Sadler F., Fox A.J., Van der Ley P., and Van der Voort E.R. Effect of sequence variation in the meningococcal PorA OMP on the immungenicity of a recombinant PorA meningococcal OMV vaccine in UK infants. In: Nassif X., Quentin-Millet M.J., and Taha M.K. (Eds). Abstracts of the eleventh international pathogenic Neisseria conference (1998), Editions E.D.K., Paris, France 178
10. Boslego J., Garcia J., Cruz C., Zollinger W., Brandt B., Ruiz S., et al. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane proteinvaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease. Vaccine 13 (1995) 821-829
11. Burrage M., Robinson A., Borrow R., Andrews N., Southern J., Findlow J., et al. Effect of vaccination with carrier protein on response to meningococcal C conjugate vaccines and value of different immunoassays as predictors of protection. Infection and Immunity 70 9 (2002) 4946-4954
12. Cadoz M. Potential and limitations of polysaccharide vaccines in infancy. Vaccine 16 (1998) 1391-1395
13. Campbell J.D., Edelman R., King J.C., Papa T., Ryall R., and Rennels M.B. Safety, reactogenicity, and immunogenicity of a tetravalent meningococcal polysaccharide-diphtheria toxoid conjugate vaccine given to healthy adults. The Journal of Infectious Diseases 186 (2002) 1848-1851
14. Carmenate T., Canaan L., Alvarez A., Delgado M., Gonzalez S., Menendez T., et al. Effect of conjugation methodology on the immunogenicity and protective efficacy of meningococcal group C polysaccharide-P64k protein conjugates. FEMS Immunology and Medical Microbiology 40 (2004) 193-199
15. Catlin B.W. Profiles of Neisseria lactamica, gonorrhoeae and meningitides, in chemically defined media. The Journal of Infectious diseases 128 2 (1973) 178-194
16. Chakraborty, P. (1996). Neisseria and Branhmella. In A textbook of microbiology (pp. 229-235). Calcutta: New Central Book Agency Limited.
17. Christodoulides M., Brooks J.L., Rattue E., and Heckels J.E. Immunization with recombinant class 1 outermembrane protein from Neisseria meningitides: Influence of liposomes and adjuvants on antibody avidity, recognition of native protein and the induction of a bactericidal immune response against meningococci. Microbiology 144 (1998) 3027-3037
18. Costantino P., Viti S., Podda A., Velmonte M.A., Nencioni L., and Rappuoli R. Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C. Vaccine 10 (1992) 691-698
19. Crowley-Luke A., Reddin K., Gorringe A., Hudson M.J., and Robinson A. Formulation and characterisation of Bordetella pertussis fimbriae as novel carrier proteins for Hib conjugate vaccines. Vaccine 19 25 (2001) 3399-3407
20. Cuello M., Cabrera O., Martinez I., Campo J.M., Camaraza M.A., Sotolongo F., et al. New meningococcal C polysaccharide-tetanus toxoid conjugate: Physico-chemical and immunological characterization. Vaccine 25 10 (2007) 1798-1805
21. Danve B., Lissolo L., Guinet F., Boutry E., Speck D., Cadoz M., et al. Safety and immunogenicity of a Neisseria meningitidis group B transferring binding protein vaccine in adults. In: Nassif X., Quentin-Millet M.J., and Taha M.K. (Eds). Abstracts of the eleventh international pathogenic Neisseria conference (1998), Editions E.D.K., Paris, France 53
22. Danzig L. Reverse vaccinology - In search of a genome-derived meningococcal vaccine. Vaccine 24 Suppl. 2 (2006) S11-S12
23. De Voe I.W., and Gilchrist J.E. Release of endotoxin in the form of cell wall blebs during vitro growth of Neisseria meningitidis. The Journal of Experimental Medicine 138 (1973) 1156-1167
24. Egan W., Frasch C.E., and Anthony B.F. Lot-release criteria, post licensure quality control, and the Haemophilus influenzae type B conjugate vaccines. The Journal of American Medical Association 273 (1995) 888-889
25. Frantz I.D. Growth requirements of meningococcus. Journal of Bacteriology 43 (1942) 757-761
26. Fusco P.C., Michon F., Tai J.Y., and Blake M.S. Preclinical evaluation of a novel group B meningococcal conjugate vaccine that elicits bactericidal activity in both mice and nonhuman primates. The Journal of Infectious Diseases 175 (1997) 364-372
27. Gold R., Lepow M.L., Goldschneider I., Draper T.L., and Gotschlich E.C. Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants. Journal of Clinical Investigation 56 6 (1975) 1536-1547
28. Gotschlich E.C., Liu T.Y., and Artenstein M.S. Human immunity to the meningococcus. The Journal of Experimental Medicine 129 (1969) 1349-1365
29. Granoff D.M., Gupta R.K., Belshe R.B., and Anderson E.L. Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination. The Journal of Infectious Diseases 178 (1998) 870-874
30. Gu X.X., and Tsai C.M. Purification of rough-type lipopolysaccharides of Neisseria meningitidis from cells and outer-membrane vesicles in spent media. Analytical Biochemistry 196 (1991) 311-318
31. Gu X.X., and Tsai C.M. Preparation, characterization, and immunogenicity of meningococcal lipooligosaccharide-derived oligosaccharide-protein conjugates. Infection and Immunity 61 (1993) 1873-1880
32. Gudlavalleti S.K., Szymanski C.M., Jarrell H.C., and Stephens D.S. In vivo determination of Neisseria meningitidis serogroup A capsular polysaccharide by whole cell high-resolution magic angle spinning NMR spectroscopy. Carbohydrate Research 341 (2006) 557-562
33. Halperin S.A., Langley J.M., Smith B., Wunderli P., Kaufman L., Kimura A., et al. Phase 1 first-in-human studies of the reactogenicity and immunogenicity of a recombinant meningococcal NspA vaccine in healthy adults. Vaccine 25 (2007) 450-457
34. Harrison L.H., Pass M.A., and Mendelsohn A.B. Invasive meningococcal disease in adolescents and young adults. The Journal of American Medical Association 286 (2001) 694-749
35. Ho M.M., Bolgiano B., and Corbel J.M. Assessment of the stability and immunogenicity of meningococcal oligosaccharide C-CRM197 conjugate vaccines. Vaccine 19 (2000) 716-725
36. Holliday M.R., and Jones C. Meeting report: WHO-co-sponsored informal workshop on the use of physicochemical methods for the characterisation of Haemophilus influenzae type B conjugate vaccines. Biologicals 27 (1999) 51-53
37. Holst J., Feiring B., Fuglesang J.E., Hoiby E.A., Nokleby H., and Aaberge I.S. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitides serogroup B disease. Vaccine 21 7/8 (2003) 734-737
38. Idanpaan-Heikkila I., Muttilainen S., Wahlstrom E., Saarinen L., Leinonen M., Sarvas M., et al. The antibody response to a prototype liposome vaccine containing Neisseria meningitidis outer membrane protein P1 produced in Bacillus subtilis. Vaccine 13 (1995) 1501-1508
39. Ioannis G., Linda M.H., and Brian M. Gellan gum. Critical Reviews in Bio-technology 20 (2000) 177-211
40. Jennings H.J., Gamian A., and Ashton F.E. N-Propionylated group B meningococcal polysaccharide mimics a unique epitope on group B Neisseria meningitidis. The Journal of Experimental Medicine 165 (1987) 1207-1211
41. Jennings H.J., Roy R., and Gamian A. Induction of meningococcal group B polysaccharide-specific IgG antibodies in mice by using an N-propionylated B polysaccharide-tetanus toxoid conjugate vaccine. Journal of Immunology 137 (1986) 1708-1713
42. Jin Z., Chu C., Robbins J.B., and Schneerson R. Preparation and characterization of group A meningococcal capsular polysaccharide conjugates and evaluation of their immunogenicity in mice. Infection and Immunity 71 9 (2003) 5115-5120
43. Jodar L., Feavers I.M., Salisbury D., and Granoff D.M. Development of vaccines against meningococcal disease. The Lancet 359 (2002) 1499-1508
44. Jodar L., Griffiths E., and Feavers I. Scientific challenges for the quality control and production of group C meningococcal conjugate vaccines. Vaccine 22 (2004) 1047-1053
45. Jones C., Lemercinier X., Crane D.T., Gee C.K., and Austin S. Spectroscopic studies of the structure and stability of glycoconjugate vaccines. Developments in Biologicals (Basel) 103 (2000) 121-136
46. Leach A., Twumasi P.A., Kumah S., Banya W.S., Jaffar S., and Forrest B.D. Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugates vaccine. The Journal of Infectious Diseases 175 (1997) 200-204
47. Lesinski G.B., and Westerink J.M.A. Vaccines again st polysaccharide antigens. Current Drug Targets Infectious Disorders 1 (2001) 225-334
48. Ley P.V., Biezen J.V., and Poolman J.T. Construction of Neisseria meningitidis strains carrying multiple chromosomal copies of the por A gene for use in the production of a multivalent outer membrane vesicle vaccine. Vaccine 13 4 (1995) 401-407
49. Lissolo L., Maitre-Wilmotte G., Dumas P., Mignon M., Danve B., and Quentin-Millet M.J. Evaluation of transferrin-binding protein 2 within the transferrin-binding protein complex as a potential antigen for future meningococcal vaccines. Infection and Immunity 63 (1995) 884-890
50. Liu T.Y., Gotschlich E.C., Jonssen E.K., and Wysocki J.R. Studies on meningococcal polysaccharides. I. Composition and chemical properties of group A polysaccharide. Journal of Biological Chemistry 246 (1971) 2849-2858
51. MacDonald N.E., Halperin S.A., Law B.J., Forrest B., Danzig L.E., and Granoff D.M. Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: A randomized controlled trial. The Journal of American Medical Association 280 (1998) 1685-1689
52. Mandrell R.E., and Zollinger W.D. Measurement of antibodies to meningococcal group B polysaccharide: Low avidity binding and equilibrium binding constants. Journal of Immunology 129 5 (1982) 2172-2178
53. Manzi A.E., Diaz S., and Varski A. High pressure liquid chromatography of sialic acids on a pellicular resin, AEC with pulsed amperometric detection: A comparison with six other systems. Analytical Biochemistry 188 (1990) 20-32
54. Martin D., Cadieux N., Hamel J., and Brodeur B.R. Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection. The Journal of Experimental Medicine 185 (1997) 1173-1183
55. Martin D., Roiux C.R., Villeneuve A., Hamel J., and Brodeur B.R. Induction of cross-reactive bactericidal and protective antibodies in animals immunized with purified recombinant meningococcal NspA protein. In: Nassif X., Quentin-Millet M.J., and Taha M.K. (Eds). Abstracts of the eleventh international pathogenic Neisseria conference (1998), Editions E.D.K, Paris, France 198
56. Massachusetts Department of public health, Massachusetts Immunization program, model standing orders, April 2004.
57. Masson L., and Holbein B.E. Influence of nutrient limitation and low pH on serogroup B Neisseria meningitidis capsular polysaccharide levels: Correlation with virulence for mice. Infection and immunity 47 2 (1985) 465-471
58. Moe G.R., Siqi T., and Granoff D.M. Molecular mimetics of polysaccharide epitopes as vaccine candidates for prevention of Neisseria meningitides serogroup B disease. FEMS Immunology and Medical Microbiology 26 (1999) 209-226
59. Moe G.R., Dave A., and Granoff D.M. Molecular analysis of anti-N-propionyl Neisseria meningitidis group B polysaccharide monoclonal antibodies. Molecular Immunology 43 (2006) 1424-1431
60. Morley S.L., and Pollard A.J. Vaccine prevention of meningococcal disease, coming soon?. Vaccine 20 5-6 (2001) 666-687
61. Musacchio A., Carmenate T., Delgado M., and Gonzalez S. Recombinant Opc meningococcal protein, folded in vitro, elicits bactericidal antibodies after immunization. Vaccine 15 (1997) 751-758
62. Muttilainen S., Idanpaan-Heikkila I., Wahlstrom E., Nurminen M., Makela P.H., and Sarvas M. The Neisseria meningitidis outer membrane protein P1 produced in Bacillus subtilis and reconstituted into phospholipid vesicles elicits antibodies to native P1 epitopes. Microbial Pathogenesis 18 (1995) 423-436
63. Norheim G., Aase A., Caugant D.A., Hoiby E.A., Fritzsonn E., Tangen T., et al. Development and characterisation of outer membrane vesicle vaccines against serogroup A Neisseria meningitides. Vaccine 23 29 (2005) 3762-3774
64. Pato T.P., De Pádua A., Barbosa R., and da Silva J.G. Purification of capsular polysaccharide from Neisseria meningitidis serogroup C by liquid chromatography. Journal of Chromatography B 832 (2006) 262-267
65. Paz M.F.D., Baruque-Ramos J., Hiss H., Vincentin M.A., Leal B., and Raw I. Polysaccharide production in batch process of Neisseria meningitidis serogroup C comparing Frantz and Catlin 6 media. Brazilian Journal of Microbiology 34 (2003) 27-32
66. Peeters C.C., Rumke H.C., Sundermann L.C., van der Voort E.M.R., Meulenbelt J., Schuller M., et al. Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine. Vaccine 14 (1996) 1009-1015
67. Peltola H. Worldwide Haemophilus influenzae type B disease at the beginning of the 21st century: Global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clinical Microbiology Reviews 13 (2000) 302-317
68. Perkins B.A., Jonsdottir K., Briem H., Griffiths E., Plikaytis B.D., Hoiby E.A., et al. Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. The Journal of Infectious Diseases 177 (1998) 683-691
69. Pettersson A., Kuipers B., Pelzer M., Verhagen E., Tiesjema R.H., Tommassen J., et al. Monoclonal antibodies against the 70-kilodalton iron-regulated protein of Neisseria meningitidis are bactericidal and strain specific. Infection and Immunity 58 (1990) 3036-3041
70. Pollard A.J., and Frasch C. Development of natural immunity to Neisseria meningitidis. Vaccine 19 (2001) 1327-1346
71. Rang H.P., Dale M.M., and Ritter J.M. Adsorption, distribution and fate of drugs. 3rd ed. (1995), Laurance Hunter pp. 91-104
72. Rauly I., Goetsch L., Haeuw J., Tardieux C., Baussant T., Bonnefoy J., et al. Carrier properties of a protein derived from outer membrane protein A of Klebsiella pneumoniae. Infection Immunity 67 11 (1999) 5547-5551
73. Ravenscroft N., D'Ascenzi S., Proietti D., Norelli F., and Costantino P. Physicochemical characterisation of the oligosaccharide component of vaccines. Developments in Biologicals (Basel) 103 (2000) 35-47
74. Ravenscroft N., Averani G., Bartoloni A., Berti S., Bigio M., Carinci V., et al. Size determination of bacterial capsular oligosaccharides used to prepare conjugate vaccines. Vaccine 17 (1999) 2802-2816
75. Reingold A.L., Hightower A.W., Bolan G.A., Jones E.E., Tiendrebeogo H., Broome C.V., et al. Age specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. The Lancet 326 8447 (1985) 114-118
76. Richmond P., Goldblatt D., Fusco P.C., Fusco J.D.C., Heron I., Clark S., et al. Safety and immunogenicity of a new Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in healthy adults. Vaccine 18 (2000) 641-646
77. Romero D.J., and Outschoorn I.M. Current status of meningococcal group B vaccine candidates: Capsular or noncapsular?. Clinical Microbiology Reviews 7 4 (1994) 559-575
78. Rosenqvist E., Musacchio A., Aase A., Hoiby E.A., Namork E., Kolberg J., et al. Functional activities and epitope specificity of human and murine antibodies against the class 4 outer membrane protein (Rmp) of Neisseria meningitidis. Infection and Immunity 67 (1999) 1267-1276
79. Satoskar, R. S., & Bhandarkar, S. D. (1993). Antibiotics effective against both Gram-positive and Gram-negative organisms In Pharmacology and pharmacotherapeutics (Vol. 2, pp. 603-604), Ramdas Bhatkal for Popular Prakashan Pvt., Ltd.
80. Simmons G., Jones N., and Calder L. Equivalence of ceftrioxane and rifampicin in eliminating nasopharyngeal carriage of serogroup B Neisseria Meningitidis. Journal of Antimicrobial Chemotherapy 45 (2000) 909-911
81. Spiro R.G. Analysis of sugar found in glycoproteins. Methods in Enzymology 8 (1966) 3-13
82. Svennerholm L. Quantitative estimation of sialic acid II, a colorimetric resorcinol hydrochloric acid method. Biochemistry and Biophysics 24 (1951) 604-611
83. Tanizaki M.M., Garcia L.R., Ramos J.B., Leite L.C.C., Hiss H., Furuta J.A., et al. Purification of meningococcal group C polysaccharide by a procedure suitable for scale-up. Journal of Microbiological Methods 27 (1996) 19-23
84. Tappero J.W., Lagos R., Ballesteros A.M., Plikaytis B., Williams D., and Dykes J. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: A randomized controlled trial in Chile. The Journal of American Medical Association 281 16 (1999) 1520-1527
85. Turula V.E., Kim J., Michon F., Pankratz J., Zhang Y., and Yoo C. An integrity assay for a meningococcal type B conjugate vaccine. Analytical Biochemistry 327 (2004) 261-270
86. Van der Ley P., Heckels J.E., Virji M., Hoogerhout P., and Poolman J.T. Topology of outer membrane porins in pathogenic Neisseria spp. Infection and Immunity 59 (1991) 2963-2971
87. Van der Voort E.M.R., Kuipers B., Brugghe H.F., Van Unen L.M., Timmermans H.A., Hoogerhout P., et al. Epitope specificity of murine and human bactericidal antibodies against PorA P1. 7, 16 induced with experimental meningococcal group B vaccines. FEMS Immunology and Medical Microbiology 17 (1997) 139-148
88. Van der Voort E.R., Van der Ley P., van der Biezen J., George S., Tunnela O., Van Dijken H., et al. Specificity of human bactericidal antibodies against PorA P1.7, 16 induced with a hexavalent meningococcal outer membrane vesicle vaccine. Infection and Immunity 64 (1996) 2745-2751
89. Wenger J.D., DiFabio J., Landaverde J.M., Levine O.S., and Gaafar T. Introduction to Hib conjugate vaccines in the non-industrialized world: Experience in four 'newly adopting' countries. Vaccine 18 (1999) 736-742
90. WHO Technical Report series (2004). Recommendations for the production and control of meningococcal group C conjugate vaccines. Annex 2, Series No. 924.
91. WHO Technical Report series (1990). Requirements of diphtheria, tetanus and pertussis and combined vaccines. Annex 2, Series No. 800.
92. Wuorimaa T., and Kayhty H. Current state of pneumococcal vaccines. Scandinavian Journal of Immunology 56 (2002) 111-129
93. Wu L., Tsai C., and Frasch C. A method of purification of bacterial R-type lipopolysaccharides (lipooligosaccharides). Analytical Biochemistry 160 (1987) 281-289
94. Wyle F.A., Artenstein M.S., Brandt B.L., Tramont E.C., Kasper D.L., Altieri P.L., et al. Immunologic response of man to group B meningococcal polysaccharide vaccines. The Journal of Infectious Diseases 126 5 (1972) 514-521
95. Zimmer S.M., and Stephens D.S. Meningococcal conjugate vaccine. Expert Opinion in Pharmacotherapy 5 4 (2004) 855-863
96. Zollinger W.D., Mandrell R.E., Griffiss J.M., Altieri P., and Berman S. Complex of meningococcal group B polysaccharide and type 2 outer membrane protein immunogenic in man. The Journal of Clinical Investigation 63 5 (1979) 836-848